Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.86 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13277359 | 0.93 | EZH2 (0.86) | EZH2HDAC1HDAC6 | |
| SCHEMBL30687988 | 0.93 | EZH2 (0.81) | EZH2HDAC1HDAC6 | |
| SCHEMBL13276782 | 0.93 | EZH2 (0.88) | EZH2HDAC1HDAC6 | |
| SCHEMBL13277416 | 0.93 | EZH2 (1.00) | EZH2HDAC1HDAC6 | |
| SCHEMBL30688033 | 0.93 | EZH2 (1.00) | EZH2HDAC1HDAC6 | |
| SCHEMBL17732395 | 0.93 | EZH2 (0.89) | EZH2HDAC1HDAC6 | |
| SCHEMBL13280847 | 0.92 | EZH2 (1.00) | EZH2HDAC1HDAC6 | |
| SCHEMBL30878122 | 0.92 | EZH2 (1.00) | EZH2HDAC1HDAC6 | |
| SCHEMBL13276839 | 0.92 | EZH2 (1.00) | EZH2HDAC1HDAC6 | |
| SCHEMBL13277491 | 0.92 | EZH2 (0.86) | EZH2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4360712-A2 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3943485-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3943485-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210379076-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-12-09 | — | — | US | disclosed |
| US-11052093-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3486234-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20200155562-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2020-05-21 | — | — | US | disclosed |
| US-10420775-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190192526-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2019-06-27 | — | — | US | disclosed |
| EP-3486234-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3150580-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9549931-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2697199-B1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150353494-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20140288041-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8765732-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2697199-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | disclosed |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. | 2012-10-18 | — | — | US | disclosed |
| WO-2012142504-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192526-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885HDAC1 1399/4885HDAC6 1883/4885 |
| US-20200155562-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885HDAC1 1399/4885HDAC6 1883/4885 |
| US-20150353494-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885HDAC1 1399/4885HDAC6 1883/4885 |
| US-11052093-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885HDAC1 1399/4885HDAC6 1883/4885 |
| US-10420775-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885HDAC1 1399/4885HDAC6 1883/4885 |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885HDAC1 1399/4885HDAC6 1883/4885 |
| US-20140288041-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885HDAC1 1399/4885HDAC6 1883/4885 |
| US-20210379076-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885HDAC1 1399/4885HDAC6 1883/4885 |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885HDAC1 1399/4885HDAC6 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.